Silvia Boffo

Silvia Boffo

Auto-generated profile, based on publicly available information

Silvia Boffo

Bristol Myers Squibb, New York, NY, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2017 in Cell Cycle
Verified
Journal Article
Open access
BDBarbara D'ANgelo
Barbara D'ANgelo
CACarlo Astarita
Carlo Astarita
SBSilvia Boffo
Silvia Boffo
MMMina Massaro-Giordano
Mina Massaro-Giordano
ACAntonella Iannuzzi Carmelina
Antonella Iannuzzi Carmelina
Antonio GiordanoAntonio Giordano
Antonio Giordano
Cell cycle reactivation in adult neurons is an early hallmark of neurodegeneration. The lipopolysaccharide (LPS) is a well-known pro-inflammatory factor that provokes neuronal cell death via glial cells activation. The retinoblastoma (RB) family includes RB1/p105, retinoblastoma-like 1 (RBL1/p107), and retinoblastoma-like 2 (Rb2/p130). Several studies have indicated that RB proteins exhibit tumor suppressor activities, and play a central role in cell cycle regulation. In this study, we assessed LPS-mediated inflammatory effect on cell cycle reactivation and apoptosis of neuronally differentiated cells. Also, we investigated whether the LPS-mediated inflammatory response can influence the function and expression of RB proteins. Our results showed that LPS challenges triggered cell cycle reactivation of differentiated neuronal cells, indicated by an accumulation of cells in S and G2/M phase. Furthermore, we found that LPS treatment also induced apoptotic death of neurons. Interestingly, we observed that LPS-mediated inflammatory effect on cell cycle re-entry and apoptosis was concomitant with the aberrant expression of RBL1/p107 and RB1/p105. To the best of our knowledge, our study is the first to indicate a role of LPS in inducing cell cycle re-entry and/or apoptosis of differentiated neuronal cells, perhaps through mechanisms altering the expression of specific members of RB family proteins. This study provides novel information on the biology of post-mitotic neurons and could help in identifying novel therapeutic targets to prevent de novo cell cycle reactivation and/or apoptosis of neurons undergoing neurodegenerative processes.

7 December 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
APAngelo Pascarella
Angelo Pascarella
CTChiara Terracciano
Chiara Terracciano
OFOlimpia Farina
Olimpia Farina
LLLuca Lombardi
Luca Lombardi
TETeresa Esposito
Teresa Esposito
SSSimone Sampaolo
Simone Sampaolo

18 February 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MGMatthew D. Galsky
Matthew D. Galsky
KAKaren A. Autio
Karen A. Autio
CCChristopher R. Cabanski
Christopher R. Cabanski
KWKristopher Wentzel
Kristopher Wentzel
Julie N. GraffJulie N. Graff
Julie N. Graff
LFLawrence Fong
Lawrence Fong
Purpose: Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer. Novel combinations may enhance immunotherapy efficacy. Patients and Methods: We conducted an open-label, noncomparative platform trial (NCT03835533) in metastatic castration-resistant prostate cancer to assess nivolumab-based combinations. The cohorts were as follows: (A) bempegaldesleukin 0.006 mg/kg and nivolumab 360 mg i.v. every 3 weeks; (B) stereotactic body radiotherapy 30 to 50 Gy, CDX-301 75 μg/kg s.c. for 5 days, poly-ICLC 1 mg intramuscularly weekly twice for 3 weeks, and nivolumab 480 mg every 4 weeks; and (C) CDX-301 75 μg/kg for 10 days, INO-5151 3 mg intramuscularly on lead-in day 8, day 1 of cycles 1 to 3, and then every 12 weeks, and nivolumab 480 mg every 4 weeks. The primary endpoint was safety; secondary endpoints included composite response rate (radiographic, PSA, or circulating tumor cell responses), 6-month disease control rate, progression-free survival, and overall survival. Serial blood and tissue samples were analyzed for pharmacodynamics and association with disease control. Results: A total of 43 patients were enrolled (n = 14, 15, and 14 in cohorts A, B, and C, respectively). Grade 3 to 4 treatment-related adverse events occurred in 10 (71%), 2 (13%), and 2 (14%) patients, respectively, with one grade 5 treatment-related adverse event in cohort A. Composite response rates were 7% (1/14), 33% (5/15), and 7% (1/14). Across cohorts, 6-month disease control was associated with preexisting memory/regulatory T cells, TNFα, and other inflammatory pathways. Conclusions: Cohort B, which combined radiotherapy with CDX-301, poly-ICLC, and nivolumab, demonstrated encouraging clinical activity. Preexisting rather than treatment-induced immune activation was associated with clinical benefit across cohorts, highlighting the importance of baseline immune fitness.

5 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
Massimo CarusoMassimo Caruso
Massimo Caruso
Rosalia EmmaRosalia Emma
Rosalia Emma
ADAlfio Distefano
Alfio Distefano
SRSonja Rust
Sonja Rust
Konstantinos PoulasKonstantinos Poulas
Konstantinos Poulas
Giovanni Li VoltiGiovanni Li Volti
Giovanni Li Volti
Cigarette smoking is the leading cause of preventable deaths worldwide. Electronic Nicotine Delivery Systems (ENDS) may reduce health risks associated with chronic exposure to smoke and their potential benefits have been the matter of intense scientific debate. Here we replicated three key published studies from the Tobacco Industry on cytotoxic and inflammatory effects of cigarette smoke and ENDS aerosol in an independent multicentric study. We aimed to establish the reliability of results and the robustness of conclusions by replicating the authors’ experimental protocols and further validating them with different techniques. We exposed human bronchial epithelial cell (NCI-H292) to cigarette smoke and to aerosol from ENDS. All the exposure were conducted at air-liquid interface to assess cytotoxicity effects of smoke and aerosol. Moreover, we aimed to assess different inflammatory mediators release (IL-6, IL-8 and MMP-1) from cells exposed to whole smoke and to smoke without particulate matter (vapor phase). We were able to replicate the results obtained in the original studies on cytotoxicity confirming that almost 80% of the cytotoxic effect of smoke is due to the vapor phase of smoke. Moreover, our results substantiated the reduced cytotoxic effects of ENDS aerosol in respect to cigarette smoke. However, our data are significantly different from the original ones in terms of inflammatory and remodeling activity triggered by smoke. Taken all together, the data obtained independently in different laboratories clearly demonstrate the reduced toxicity of ENDS products compared to cigarettes and thus providing a valuable tool to the harm reduction strategies in smokers.

21 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
KCKatie M. Campbell
Katie M. Campbell
DCDaniel Guorui Chen
Daniel Guorui Chen
ZBZaid E. Bustami
Zaid E. Bustami
NDNataly Naser Al Deen
Nataly Naser Al Deen
EMEgmidio Medina
Egmidio Medina
ARAntoni Ribas
Antoni Ribas
In the phase 2 trial SWOG S1616 (NCT03033576), patients with advanced melanoma with primary resistance to anti-PD-1/L1 therapies had improved outcomes on the combination of the anti-CTLA-4 antibody ipilimumab with continued anti-PD-1 with nivolumab, over ipilimumab alone. Baseline biopsies from patients responsive to combination therapy had increased transcriptomic expression of complement by myeloid cells, interferon pathways by endothelial cells, and oxidative phosphorylation and lipid metabolism by melanoma cells. Using spatial proteomics, some on-therapy biopsies from patients responding to combination therapy had networks of activated CD8 T cells nearby melanoma cells, while others had T cells and myeloid cells, reflective of different timepoints in a dynamic antitumor response. Conversely, biopsies from patients progressing on combination immunotherapy displayed impaired T-cell infiltration adjacent to plasma cells. Our results define cellular neighborhoods and transcriptomes in melanoma biopsies when reversing resistance to anti-PD-1 with the addition of anti-CTLA4, and plasma cell sheets in non-responding biopsies.

17 June 2026
Verified
Other
Open access
PDF file
MGMatthew D. Galsky
Matthew D. Galsky
KAKaren A. Autio
Karen A. Autio
CCChristopher R. Cabanski
Christopher R. Cabanski
KWKristopher Wentzel
Kristopher Wentzel
Julie N. GraffJulie N. Graff
Julie N. Graff
LFLawrence Fong
Lawrence Fong
Figure S1 shows the gating strategy for mass cytometry (CyTOF).